Latest news with #RegeneronPharmaceuticals
Forbes
a day ago
- Business
- Forbes
REGN Stock Undervalued At $500?
Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was anticipated to become a blockbuster drug, with peak sales projections from Sanofi estimated between $2 billion and $6 billion. This recent occurrence has intensified the existing pressures on REGN stock. At present, trading at $490, the stock has decreased 60% from its 52-week peak of about $1,200. A large portion of this downturn can be ascribed to the company's less-than-expected performance, especially concerning its existing blockbuster treatment, Eylea. To add to Regeneron's challenges, the U.S. Food and Drug Administration (FDA) recently rejected a pre-filled syringe variant of Eylea HD, citing problems with a third-party supplier. In light of the significant drop in Regeneron's stock price, a natural question emerges: is REGN now a viable buying opportunity? From a valuation standpoint, the stock seems undervalued, indicating an attractive entry point for investors. We believe there is little reason for long-term concern with REGN stock, rendering its current valuation notably low. Our conclusion is derived from a thorough analysis that compares REGN's current valuation with its recent operating performance and historical financial health. Our evaluation of Regeneron Pharmaceuticals across essential parameters—Growth, Profitability, Financial Stability, and Downturn Resilience—suggests that the company continues to exhibit a very strong operational performance and financial condition, as elaborated further below. Nevertheless, for investors seeking lower volatility than that of individual stocks, the Trefis High Quality portfolio offers an alternative — having outperformed the S&P 500 and delivered returns exceeding 91% since its inception. Additionally, see – Buy, Sell, or Hold HIMS Stock? When considering the cost per dollar of sales or profit, REGN stock appears slightly undervalued compared to the broader market. Regeneron Pharmaceuticals' Revenues have seen a slight decline over recent years. Regeneron Pharmaceuticals' profit margins are significantly higher than those of most companies in the Trefis coverage universe. Regeneron Pharmaceuticals' balance sheet appears very robust. REGN stock has experienced an impact that was slightly better than the benchmark S&P 500 index during various recent downturns. Concerned about the influence of a market crash on REGN stock? Our dashboard – How Low Can Regeneron Pharmaceuticals Stock Go In A Market Crash? – includes a comprehensive analysis of the stock's performance during and after past market crashes. In conclusion, Regeneron Pharmaceuticals' performance across the mentioned parameters is summarized as follows: Regeneron has demonstrated strong performance across crucial financial metrics, and we contend this is not fully captured in its current stock valuation, which renders it an attractive investment. This substantiates our assertion that REGN is a stock worth buying. The recent clinical trial setback for itepekimab will most likely postpone its launch, as the drug will require further trials. Nevertheless, Regeneron stands to gain significantly from the strong growth of Dupixent, a drug created in partnership with Sanofi. Dupixent's sales rose 19% to $3.7 billion last quarter, with potential peak annual sales surpassing $20 billion. Furthermore, Regeneron has a promising pipeline with over a dozen programs currently in late-stage trials, suggesting future growth opportunities. Even though a setback in a clinical trial and declining Eylea sales may logically lead to a compression in valuation multiples, we believe the selling pressure on REGN stock at values below $500 is excessive. We think investors can exploit this current dip as a buying chance for strong long-term gains. Nevertheless, prior to making any investment choices, it's critical to consider the associated risks. Any adverse outcomes from ongoing clinical trials, particularly related to its COPD treatment, could result in further declines in the stock. Moreover, during periods of broader market downturns stemming from macroeconomic uncertainties, REGN stock could also decrease. Although Regeneron has historically outperformed the broader market during certain recent corrections, it remains susceptible to sharp declines. Separately, see – Plug Power's Hydrogen Hopes Dashed? While REGN stock appears promising, investing in a single stock can present risks. Conversely, the Trefis High Quality (HQ) Portfolio, consisting of 30 stocks, has a history of consistently outperforming the S&P 500 over the past 4 years. Why is that? Collectively, HQ Portfolio stocks have delivered better returns with less risk compared to the benchmark index; presenting less volatility, as demonstrated in HQ Portfolio performance metrics.
Yahoo
3 days ago
- Business
- Yahoo
Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial
Regeneron Pharmaceuticals announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities. Despite these positive developments, the company's shares fell by 17% last week. In contrast, the broader market rose by 1.7%. This divergence might suggest that the market's reaction to Regeneron's news was mixed or that other factors were at play. While the trial success and new partnership could eventually strengthen Regeneron's position, the immediate market response appears to have worked against the broader upward market trend. Buy, Hold or Sell Regeneron Pharmaceuticals? View our complete analysis and fair value estimate and you decide. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent favorable trial results and partnership announcements by Regeneron Pharmaceuticals hold potential significance for its long-term narrative. With the company's strategic focus on expanding drug franchises and enhancing R&D capabilities, these developments could positively influence future revenue and earnings forecasts. However, the immediate 17% drop in share value indicates that investors may have other concerns or that expectations were misaligned with the results. This decrease contrasts with a 1.7% rise in the broader market. Over a five-year period, Regeneron's total shareholder return, accounting for share price and dividends, was a 17.65% decline. In the past year, Regeneron underperformed both the US Biotechs industry, which returned a 12.5% decline, and the general US market, which gained 11.5%. This extended underperformance suggests a challenging environment for Regeneron relative to broader industry and market trends. With analysts projecting revenue and earnings growth, the company needs to align these forecasts with current market realities. With a price target of US$772.13 and a share price discount nearing 57%, Regeneron's current valuation indicates a gap between market sentiment and bullish analyst expectations. Investors should assess how these developments influence long-term profitability and market positioning to determine potential stock value fluctuations. Learn about Regeneron Pharmaceuticals' historical performance here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:REGN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 days ago
- Business
- Yahoo
S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a key report revealed softening inflation. Regeneron Pharmaceuticals shares plummeted after the company's experimental COPD treatment fell short of expectations in a late-stage clinical trial. Makeup seller Ulta Beauty reported better-than-expected quarterly sales and profits, and its shares U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal Consumption Expenditures data showed that inflation fell more than expected in April. The S&P 500 staged a Friday-afternoon rally, coming back from deeper in negative territory to end with a loss of less than 0.1%. The Nasdaq was down 0.3%, while the Dow held onto a gain of 0.1%. The Nasdaq and S&P logged their strongest months since 2023. Read Investopedia's full coverage of today's trading here. Shares of Regeneron Pharmaceuticals (REGN) plunged 19%, dropping the most of any stock in the S&P 500. The losses came after an experimental treatment for chronic obstructive pulmonary disease in former smokers, developed by Regeneron in collaboration with Sanofi (SNY), failed to meet primary endpoints in a Phase 3 trial. The companies said they are reviewing the data and will work with regulators to outline potential next steps. U.S.-listed shares of Sanofi slid 5.7%. Cooper Cos. (COO) shares dropped 15% after the contact lens manufacturer reduced its full-year outlook for organic growth while edging out consensus sales and adjusted profit estimates with its fiscal second-quarter results. Analysts at JPMorgan downgraded Cooper stock to "neutral" from "overweight," citing the company's uneven execution and the possibility of a sustained slowdown in market trends. Shares of Eastman Chemical (EMN), known for its specialty plastics and adhesives, fell 3.8%. The company announced that its molecular recycling project in Longview, Texas, which was previously expected to receive $375 million in public funding, was among 24 awards revoked by the Department of Energy. Cosmetics retailer Ulta Beauty (ULTA) topped sales and profit estimates for its fiscal first quarter and lifted its outlook for the full year. CEO Kecia Steelman highlighted contributions from new and exclusive brands as well as strong sales of fragrance products, noting that consumers were turning to beauty products "as a comfort and escape from the stress of macro uncertainty." Ulta shares skyrocketed 12%, scoring the S&P 500's top daily performance. Shares of Palantir Technologies (PLTR) jumped 7.7% as a New York Times report indicated that the Trump administration has expanded the data analytics software firm's role in government data-sharing initiatives. The tech company, which has lucrative contracts with the federal government and Defense Department, is reportedly engaged in efforts to improve access to data across government agencies. Enphase Energy (ENPH) stock advanced 5.5%. Shares of the solar microinverter manufacturer came under heavy pressure alongside other renewable energy players after the House of Representatives passed a tax and spending bill that would eliminate certain incentives for clean energy projects, including a federal tax credit for the installation of solar rooftop systems. Enphase Energy shares dropped to a 52-week low on May 22, the day the bill was passed, but have staged a partial recovery since. Costco Wholesale (COST) stock added 3.1% after the bulk retailer's quarterly revenue and net income edged out consensus forecasts. Same-store sales also grew more than expected. Analysts have suggested that high-margin membership revenue could provide Costco with some flexibility to navigate tariff-related cost pressure without raising prices. Read the original article on Investopedia
Yahoo
4 days ago
- Business
- Yahoo
Regeneron stock sinks over trial data for smoker's lungs drug
Regeneron Pharmaceuticals (REGN) shares sank in Friday trading after the company published disappointing drug trial results for a treatment on a condition called smoker's lungs. The drug was co-developed with Sanofi (SNY, Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination Overtime to speak more on this. Regeneron has put up a bid to acquire genetic testing firm 23andMe (ME) after the company filed for bankruptcy. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Well shares of Regeneron Pharmaceuticals, they're sinking. The move lower comes as trial results for the company's co-developed experimental drug with Sanofi disappoints. Joining us now with more is Yahoo Finance's, Angelique Clamontange. That's right, Josh. They got news of uh, the drug not necessarily meeting the end points that it was supposed to. The stock down about 19%, uh closing at that rate today. And we saw that this is a drug that the company had uh, had co-developed with Sanofi and it's supposed to address chronic obstructive pulmonary disease and they're looking at former smokers who have basically inflammation or damage to their lung tissue, making it harder to breathe. Now the primary endpoint of reducing that kind of obstruction they had one trial that met the endpoint and one that didn't. So that mixed result is really what caused the pressure on the stock today. And this of course coming after Regeneron came to if you will save the day and took 23andMe out of bankruptcy recently. So they'd really gotten a bump in their stock because of that and now just kind of washed away and hitting a four-year low today. And Ange, why does this matter more for Regeneron than Sanofi? Yeah, Regeneron has had a little bit of questions surrounding it. Um, you know, some of the uh, analysts did uh, have looked at its pipeline and that's been sort of where the pressure's coming from. We saw some downgrades today just on this news. RBC and Wells Fargo punishing that stock because of the, the news today. Regeneron doesn't have any near term blockbusters and this was supposed to essentially be it. It's important to note that they already are working with Sanofi on a different product that did hit, that has been on the market. Dupixent, and it did get approved for COPD last year. That drug brings in about 14 billion and so this was looking to be sort of on the same range. Uh, even though that drug does address a number of other diseases but it could have been another blockbuster for Regeneron and now without that their near term pipeline is in question. Ange, thanks so much, appreciate it. Have a great weekend. You too.
Yahoo
4 days ago
- Business
- Yahoo
Regeneron stock sinks over trial data for smoker's lungs drug
Regeneron Pharmaceuticals (REGN) shares sank in Friday trading after the company published disappointing drug trial results for a treatment on a condition called smoker's lungs. The drug was co-developed with Sanofi (SNY, Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination Overtime to speak more on this. Regeneron has put up a bid to acquire genetic testing firm 23andMe (ME) after the company filed for bankruptcy. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
